Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		<ul><li>a) Statistical methods</li><li>b) Randomization evaluated?</li></ul>	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	(yes, no) If yes: variables, potential differences and possible adjustment performed noted? c) Numbers included in analyses d) Intention-to-treat analyses (yes/no/not mentioned)	
[19]	<ul> <li>a) Stratified, cluster (stratification at surgeon level (experience of surgeon's breast cancer practice); Within each stratum randomization was performed in blocks of four.</li> <li>b) N(Surgeons)=60; N(Patients)=335, n- CM=169, n- control=166</li> </ul>	Primary: cancer-specific therapies received (after 6 months) Secondary: patient evaluations of the decision-making process; arm function on affected side. (2 (and 12) months after diagnosis.)	Primary: medical records audit (A summary measure of receipt of appropriate therapy was created based on published consensus recommendations; ref) Secondary: home interview based on pilot tested questionnaires on logistics, decision-making, satisfaction and tamoxifen prescription (?) and objective assessment of arm functions (?).	<ul> <li>a) Differences in baseline characteristics and in outcomes between control and intervention groups were assessed using chi- square.</li> <li>(Cluster effect at surgeon level was adjusted for.)</li> <li>b) Yes. No difference found (demographics, cognitive function, and stage of disease)</li> <li>c) Primary outcome: n-CM: 169 and n-control 166 Secondary outcomes: ?</li> <li>d) Yes</li> </ul>	Primary: More women in the intervention group saw a radiation oncologist at their initial evaluation (36.0  vs.  19.3%, P=0.006), received breast-conserving surgery (28.6 vs. 18.7%, p=0.031) and radiation therapy (36.0%  vs.  19.0%; P=0.003). Secondary: Intervention group was significantly more satisfied (more components; p<0.05) and had significantly more normal or near-normal range of arm motion (93 vs. 84%, p=0.037). (Several subgroup analyses: "Women with poor social support were most likely to benefit from the nurse CM intervention.")
[23]	a) Simple, two-arm randomization. b) N=210, n-int=106, n-control=104	-Quality of Life (QoL) (At enrolment + 1, 3, 6, 12, 18, 24 months after enrolment.) -Cost data (24 months after date of diagnosis).	<ul> <li>-QoL measured with three self-administered questionnaires:</li> <li>1. MUIS: uncertainty</li> <li>2. POMS: mood</li> <li>3. FACT-E: well-being/ QoL on six dimensions.</li> <li>(yes, all validated + ref)</li> <li>-Charges and reimbursements were collected from billing systems.</li> <li>Length of hospitalization and number of visit to health care</li> </ul>	<ul> <li>a) -Univariate analyses of QoL data: t-test + chi-square /Fisher's exact test.</li> <li>Multiple regression for repeated QoL measures using baseline scores as a covariate.</li> <li>-Costs: Univariate analysis + multivariate regression.</li> <li>b) Yes (variables: demographics and disease characteristics).</li> <li>Difference found: Intervention group women had lower</li> </ul>	Uncertainty: Intervention group had less uncertainty at 1, 3 and 6 months (p<0.05). Effect size not specified. Mood and well-being: no sign. diff. between int. and control group. Overall costs: no difference found including subgroup analyses. (Some subgroups benefitted significantly from APN, e.g. unmarried women and women with no family history of breast cancer).

**Table 2**: Randomization, data collection, analyses and results

Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		a) Statistical methods b) Randomization evaluated?	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	<ul> <li>(yes, no)</li> <li>If yes: variables, potential</li> <li>differences and possible</li> <li>adjustment performed noted?</li> <li>c) Numbers included in</li> <li>analyses</li> <li>d) Intention-to-treat analyses</li> <li>(yes/no/not mentioned)</li> </ul>	
			provider were recorded. Cost of APN services were based on time logs.	histology (p=0,04) and more received adjuvant hormone therapy (p=0,03); adj. performed. c) QoL: ? Cost data: N=152 (n-int=78, n- contro=74; 58 excluded because of missing data) d) Not mentioned	
[25]	a) Three-arm simple randomization b) N=166, Numbers assigned to each of the "arms" N/A.	-Measures of Patient Psychosocial Responses (Five interviews at 6-week interval; first before group assignment.) -Number of hospitalizations -Length of Stay (LOS) (continuously through 24 weeks).	<ul> <li>-Psychosocial responses: Interview questionnaire (in- person or telephone ?); Scales: Symptom distress (The Symptom Distress Scale); Pain(McGill-Melzack Pain Questionnaire); Current Concerns (Weisman and Worden's Inventory of Current Concerns); Mood state (Profile of Mood States)</li> <li>Functional status (General Health Rating Index) (ref to all above)</li> <li>-A Medical Record Review Instrument was developed.</li> </ul>	<ul> <li>a) Primary analyses: repeated measures and analysis of variance for each dependent variable (univariate mixed model and multivariate model). Plot of means for the core measures.</li> <li>b) Yes. No difference on demographics, Starting points for depending variables were discrepant for which reason adjustment was performed (Potential bias of adj. was discussed).</li> <li>c) Patient psychosocial responses: 78 patients completing four interviews (numbers in each group not stated).</li> <li>Number of hospitalizations: 77 of 78 completing four interviews (n- OHC=24, n-SHC=27, n-OC=26).</li> <li>LOS: 52 (had been hospitalized) of 78 completing four interviews (n-OHC=14, n-SHC=18, n-</li> </ul>	Psychosocial Responses : Significant difference between the profiles of the two nursing groups and the office care group with regards to adjusted Symptom Distress (P=0.03) and adjusted Enforced Social Dependency (P=0.02) in favour of home care nursing. The OC group rather steadily reported improved health perceptions over time, whereas the two treatment groups reported worse health perceptions (p<0.05). No of hospitalizations and LOS: No significant differences

Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		<ul><li>a) Statistical methods</li><li>b) Randomization evaluated?</li></ul>	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	<ul> <li>(yes, no)</li> <li>If yes: variables, potential</li> <li>differences and possible</li> <li>adjustment performed noted?</li> <li>c) Numbers included in</li> <li>analyses</li> <li>d) Intention-to-treat analyses</li> <li>(yes/no/not mentioned)</li> </ul>	
				OC=20). d) Not mentioned	
[24]	a) Simple randomization. b) N=375, n- intervention=190, n- control=185	Primary: Length of survival (up to 44 months of follow up) Secondary: To identify psychosocial and clinical predictors of patient survival (i.e. depressive symptoms, symptom distress, functional status, co-morbidities, length of hospital stay, age, and cancer stage). (baseline, 3, and 6 months)	Survival status was ascertained by letter, telephone, or death certificates (?) Demographics: "obtained at accrual" (?) Stage of disease: Surgical pathology reports and physician's discharge summary (?) Psychosocial questionnaires : Center for Epidemiological Studies-Depression Scale (CES- D), Symptom Distress Scale (SDS), and Enforced Social Dependency Scale (ESDS) (ref to all)	<ul> <li>a) Stratified log-rank test was used to compare groups. Kaplan- Meier curves stratified by stage of disease at diagnosis.</li> <li>Cox's proportional hazards regression model to compute adjusted hazard ratios (=HR; Proportional hazards assumption was Schoenfeld tested)</li> <li>b) Yes (demographics and clinical variables; more late stage patients in intervention group (p=0,013). Adjusted and stratified analyses performed.</li> <li>c) Survival status for all 375 included patients were obtained Psychosocial questionnaire responderse: time 0: n-int=190 n- UC=185; time 3 months: n- int=163, n-UC= 153; time 6 months: n-int=158, n-UC=147).</li> <li>d) Not mentioned</li> </ul>	Non-stratified analyses revealed no difference in survival status between groups (p=0,129). Stratified analyses: Late-stage patients' 2-year survival were 66.7% in int. group vs. 39.6% in control group (p<0.05). Adjusted for psychosocial and clinical covariates: Usual care had death-HR=2.04 (95% CI 1.33-3.12, p=0.001) Late stage usual care patients had adjusted death-HR=4.55 (CI 2.92-7.08; p<0.001) Outcomes of psychosocial questionnaires were not mentioned at all in results paragraph.

Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		<ul><li>a) Statistical methods</li><li>b) Randomization evaluated?</li></ul>	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	(yes, no) If yes: variables, potential differences and possible adjustment performed noted? c) Numbers included in analyses d) Intention-to-treat analyses (yes/no/not mentioned)	
[26]	a) Block-randomization (blocks of 10; rationale not outlined) b) N=275; n- AICCP=133, n- UC=142; N-surrogates (relatives)=168, n- sAICCP =76, n- sUC=92.	<ul> <li>-Patients' evaluations of patient/provider communication, satisfaction with care and attitudes about participation in treatment planning (enrolment, at 3 and 6 months)</li> <li>-Surrogates' experiences with the health care system. (3 months postenrolment.)</li> <li>-Costs (end of study)</li> <li>-Advance directives (AD) and do-not-resuscitate and intubate (DNR[I]) (enrolment, 3 and 6 months)</li> </ul>	Patient/provider communication, satisfaction with care: Investigator-constructed, 10- item scale (?, but "reliability tested on enrolment") Participation in treatment planning was assessed by a single item (?; "asked" – questionnaire or interview?) Surrogates' experiences (problems in 7 domains were averaged to create a single overall rating): Modified EOL Family Interview (ref; "asked" - questionnaire or interview?) Costs: Program contact, salary, and overhead costs collected from 3 sites (the VAMC patients). Other costs: medical records for VAMCs patients. AD and DNR(I): VAMC participants' medical records	<ul> <li>a) -Patients' evaluations: Scores were examined for effects of group, time, and group-by-time interaction using a random effects regression model.</li> <li>-Surrogates' exp.: Post- intervention scores t-test compared.</li> <li>-AD: Chi-square comparison and t-test. Kaplan-Meier curves comparison of group membership and time to completion of ADs.</li> <li>-Costs: F test</li> <li>Effect sizes were calculated for most outcomes.</li> <li>b) Yes, (Patients' demographics and diagnoses (and later survival), no diff.; surrogates: No of participants, sex and relationship: no diff.)</li> <li>c) Patients and surrogates evaluations: ?</li> <li>Mean per case AICCP costs: Data for 70 VAMC patients.</li> <li>Other costs:169 VAMC patients.</li> <li>(AICCP=93, UC=76).</li> <li>AD etc: data on 180 VAMC patients (AICCP= 85 and UC=95)</li> <li>d) Yes, all outcomes (18 patients crossed over to AICCP, two</li> </ul>	Patient satisfaction with care: Significant group-by-time interaction in favour of the AICCP group (Effect size 0.18, $P = 0.03$ ). (Effect size is the ratio of the estimated treatment effect.) Surrogates post-test scores: Fewer problems (with the spiritual and emotional support delivered) reported by AICCP surrogates than UC surrogates (effect size 0.39, p=0.03) Costs: no stat. sign diff. AD: Median time to completion of first AD: AICCP=46 days vs. UC= 238 days (log-rank P=0.02) Proportion of patients having completed at least one AD, and the mean numbers of ADs per patient were sign. higher for the AICCP group at both 3 and 6 months (p=0.01).

Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		a) Statistical methods b) Randomization evaluated?	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	<ul> <li>(yes, no)</li> <li>If yes: variables, potential</li> <li>differences and possible</li> <li>adjustment performed noted?</li> <li>c) Numbers included in</li> <li>analyses</li> <li>d) Intention-to-treat analyses</li> <li>(yes/no/not mentioned)</li> </ul>	
				patients crossed over to UC. Some VAMCs inpatient units implemented AICCP as usual care during the study)	
[22]	a) Stratified randomisation (six strata; three strata based on unmet need status, and two strata based on gender). b) N=259, n-CM=130, n-control=129	-Unmet needs (assessed by patients) -Reported symptom severity -Several dimensions of QoL -Formal service utilization (Data collection: At baseline, at 3 and 6 months)	-Aspects of daily living (three unmet needs-categories) (ref); -Standard questions on symptom severity (?) -Spitzer's physical "QoL Index"(ref), five-item mood state score from SF-36 (ref), and a specially developed 4-item scale measuring patient experienced disruptions in treatment (?) All above: Telephone interviews -Service utilization: Patients' reports and audit of patients' medical records.	<ul> <li>a) Chi-square and analysis of variance to test differences between intervention and control groups</li> <li>b) yes (no difference found on baseline demographic, medical and need status)</li> <li>d) 3 months: n-CM=109, n- control=108, 6 months: n- CM=93, n-control=92</li> <li>e) Not mentioned; unclear if 11 CM group patients who refused CM services were followed up and in which group they were analysed (?)</li> </ul>	No statistically significant differences were observed on any outcome measure for the overall sample as well as for selected "at-risk" patient subgroups.

Ref	a) Randomization type b) N, n-intervention, and n-control	Outcomes		<ul><li>a) Statistical methods</li><li>b) Randomization evaluated?</li></ul>	Main results
		Outcomes of interest* (Time of measure)	Outcome source (Validity account <sup>#</sup> )	(yes, no) If yes: variables, potential differences and possible adjustment performed noted? c) Numbers included in analyses d) Intention-to-treat analyses (yes/no/not mentioned)	
[27]	a) Stratified randomisation according to hospital and treatment intent (rationale and numbers of strata not outlined) b) N=203 (n-nurse led follow-up=100, n- control=103)	Primary: QoL and patients' satisfaction at three months (assessed at baseline, 3, 6, and 12 months) Secondary: Overall survival, Symptom-free survival, Progression-free survival. GPs' satisfaction (at the ord of study participation)	-EORTC QLQ-C30 and module about lung cancer. (ref) -Patient satisfaction questionnaire incorporating three validated measures and tested in a pilot study (ref) No information on source of secondary outcomes.	<ul> <li>a) QoL + satisfaction: Mann-Whitney U test</li> <li>Survival: Kaplan-Meier</li> <li>Costs: Mann-Whitney U test.</li> <li>b) Yes (no difference found on clinical, OoL and pat sat baseline variables)</li> <li>c) 3 months: n-int=76, n-control=74; 6 months: n-int=53, n-control= 58; 12 months: n-int=26, n-control=29</li> <li>d) Net mentioned, but it uses</li> </ul>	Int. group had less dyspnoea (p=0,03; a QoL score) and significantly higher satisfaction in each subscale at three months. Int. group had longer time to symptomatic progression (p=0,01). Significant change in pattern of service use, but no difference in readmission rates. Significantly more patients in int. group died at home (p=0,04).
		end of study participation). Service use (3, 6 and 12 months) and cost effectiveness		d) Not mentioned, but it was mentioned that no intervention group patients reverted to medical follow-up.	No difference in costs, and GP satisfaction.

? Not to be found in the article

\* Outcomes of interest: if primary and secondary was not indicated, "-" are used in front of each \*Validity account categorised as follows: ?: validity not mentioned at all; ref: reference(s) quoted; yes: it is mentioned that measure is validated